Novartis to buy The Medicines Company for $9.7bnNovartis is to buy The Medicines Company and its cholesterol-lowering drug for $9.7 billion, confirming press speculation. The Share XNovartis to buy The Medicines Company for $9.7bnhttps://pharmaphorum.com/news/novartis-to-buy-the-medicines-company-for-9-7bn/
Novartis eyes $5bn The Medicines Company acquisition – reportsNovartis is leading a group of companies that are considering buying US pharma The Medicines Company searching for Share XNovartis eyes $5bn The Medicines Company acquisition – reportshttps://pharmaphorum.com/news/novartis-eyes-5bn-the-medicines-company-acquisition-reports/
TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?Cardiologists only had to wait a few days after The Medicines Company teased top-line results with its cholesterol-lowering Share XTMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?https://pharmaphorum.com/news/tmcs-inclisiran-impresses-at-esc-but-will-it-surpass-pcsk9-rivals/
TMC inches closer to inclisiran approval with long-term safety dataThe Medicines Company (TMC) has bet the proverbial farm on cholesterol-lowering candidate inclisiran and is celebrating new safety Share XTMC inches closer to inclisiran approval with long-term safety datahttps://pharmaphorum.com/news/tmc-inches-closer-to-inclisiran-approval-with-long-term-safety-data/